A Phase 1 interventional study of KST-6051 and Gemcitabine/nab-paclitaxel in KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) and KRAS-mutant Colorectal Cancer (CRC), sponsored by Kestrel Therapeutics, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Kestrel Therapeutics, Inc. · Phase 1, Interventional, and Treatment
How we know · 19 judgments
Drug: Gemcitabine/nab-paclitaxel · Drug: Cetuximab · Drug: Pembrolizumab · Drug: mFOLFOX6 · Drug: FOLFIRI · Drug: Pemetrexed · Drug: Carboplatin
KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel · KST-6051 Dose Escalation Combination Therapy with Cetuximab · KST-6051 Dose Escalation Combination Therapy with Pembrolizumab · KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors · KST-6051 Dose Expansion Monotherapy in Later-line Settings · KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel · KST-6051 Dose Expansion Combination Therapy with Cetuximab · KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI · KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.
Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 134th largest by planned enrollment of the 1,908 interventional ones that give a count, is one of 112 that started in 2026, is one of 448 in phase 1, reaches primary completion later than 440 of the 638 other live ones, and was the 2,392nd registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–77 · Healthy volunteers
Fred Hutchinson Cancer Center · Sites in United States
Ages 50–80 · Healthy volunteers
Roswell Park Cancer Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,462 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 660 · Phase 2 866 · Phase 3 179 · Phase 4 21
First in 1990; this study’s year is marked. 112 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 545 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 48 across the 1,908 interventional studies, 123 across the 442 observational. Of the 1,674 that completed or were terminated, 583 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
620 of 2,462 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Kestrel Therapeutics, Inc. as lead sponsor.
Kestrel Therapeutics, Inc. has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
243 of the studies in Lung Neoplasms with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07499674Phase 3Vergent Bioscience, Inc.Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | 2026-12 |
| NCT06151574Phase 3Boehringer IngelheimBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | 2026-12-10 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT04093167Phase 3Canadian Cancer Trials GroupStudy of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | 2026-12-31 |
| NCT03391869Phase 3M.D. Anderson Cancer CenterNivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | 2027-03-31 |
Add all 243 to your calendar (.ics) → With an account.
Among the 2,462 studies in Lung Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.
This is a first-in-human, phase 1, open-label, multicenter clinical trial designed to evaluate safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics and preliminary activity of orally administered KST-6051 as monotherapy or in combination with other anticancer agents. The trial seeks to enroll adults with advanced or metastatic KRAS mutant solid tumors including but not limited to pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer whose cancers have progressed after prior therapy or in whom standard therapy was not tolerated. The trial includes a dose escalation phase in which higher doses of KST-6051 will be given in subsequent groups of participants. The trial also includes a dose expansion phase to further investigate KST-6051. Participants can stay in the trial as long as they benefit from the treatment and can tolerate it.
The criteria were revised on the registry on Oct 15, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion/exclusion criteria are specified in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sequential cohorts with increasing doses of KST-6051 as monotherapy will be evaluated to determine recommended dose(s) for expansion (RDE\[s\]).
Drug: KST-6051
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of gemcitabine/nab-paclitaxel will be evaluated in participants with previously treated PDAC.
Drug: KST-6051 · Drug: Gemcitabine/nab-paclitaxel
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of cetuximab will be evaluated in participants with previously treated KRAS-mutant mCRC.
Drug: KST-6051 · Drug: Cetuximab
Sequential cohorts with increasing doses of KST-6051 as combination therapy with a standard dose of pembrolizumab will be evaluated in participants with first- or second-line KRAS-mutant NSCLC.
Drug: KST-6051 · Drug: Pembrolizumab
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in PDAC after 1 or 2 prior lines of therapy.
Drug: KST-6051
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in mCRC after 1 or 2 prior lines of therapy.
Drug: KST-6051
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in NSCLC after 1 or 2 prior lines of therapy.
Drug: KST-6051
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in prior RAS/KRAS inhibitor-treated solid tumors.
Drug: KST-6051
Dose expansion cohorts will be evaluated to further investigate KST-6051 as monotherapy in selected KRAS-mutant biliary tract cancer, endometrial cancer (EC), or other solid tumors in later-line settings.
Drug: KST-6051
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with gemcitabine/nab-paclitaxel in 1L PDAC.
Drug: KST-6051 · Drug: Gemcitabine/nab-paclitaxel
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab in 2L/3L CRC.
Drug: KST-6051 · Drug: Cetuximab
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with cetuximab and mFOLFOX6 or FOLFIRI in 1L CRC.
Drug: KST-6051 · Drug: Cetuximab · Drug: mFOLFOX6 · Drug: FOLFIRI
Dose expansion cohorts will be evaluated to further investigate KST-6051 as combination therapy with pembrolizumab and pemetrexed/carboplatin in 1L NSCLC.
Drug: KST-6051 · Drug: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin
KST-6051 will be administered orally as a tablet.
Gemcitabine/nab-paclitaxel will be administered intravenously (IV).
Cetuximab will be administered IV.
Pembrolizumab will be administered IV.
mFOLFOX6 will be administered IV.
FOLFIRI will be administered IV.
Pemetrexed will be administered IV.
Carboplatin will be administered IV.
Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)
Time frame: Up to Day 21 of Treatment Cycle 1
Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.
Time frame: Up to approximately 2 years
Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)
Clinically significant changes in safety assessments (vital signs, physical examinations, electrocardiograms, and clinical laboratory tests) are to be reported as adverse events.
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)
Time frame: Up to approximately 2 years
Dose Escalation Cohorts: Maximum Observed Blood Concentration (Cmax) of KST-6051 Alone
Time frame: Up to Week 6
Dose Escalation Cohorts: Cmax of KST-6051 in Combination with Other Agents
Time frame: Up to Week 6
Dose Escalation Cohorts: Time to Achieve Cmax (Tmax) of KST-6051 Alone
Time frame: Up to Week 6
Dose Escalation Cohorts: Tmax of KST-6051 in Combination with Other Agents
Time frame: Up to Week 6
Dose Escalation Cohorts: Half-life (t1/2) of KST-6051 Alone
Time frame: Up to Week 6
Dose Escalation Cohorts: t1/2 of KST-6051 in Combination with Other Agents
Time frame: Up to Week 6
Dose Escalation Cohorts: Area Under the Blood Concentration-time Curve (AUC) of KST-6051 Alone
Time frame: Up to Week 6
Dose Escalation Cohorts: AUC of KST-6051 in Combination with Other Agents
Time frame: Up to Week 6
Dose Escalation Cohorts: ORR
Time frame: Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Disease Control Rate (DCR)
Time frame: Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Duration of Overall Response (DOR)
Time frame: Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Progression-free Survival (PFS)
Time frame: Up to approximately 2 years
Dose Escalation and Dose Expansion Cohorts: Overall Survival (OS)
Time frame: Up to approximately 2 years
Dose Escalation Cohorts: Duration of Stable Disease
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Time to Response (TTR)
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Number of Participants With TEAEs
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Number of Participants with Dose Interruptions, Dose Reductions, and Discontinuations
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Relative Dose Intensity and Treatment Exposure
Time frame: Up to approximately 2 years
Dose Expansion Cohorts: Concentration of KST-6051 in the Whole Blood After Multiple Dose Administration
Time frame: Up to Week 6
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.
Of 164 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 24 months is below that.
Counting every sponsor, half of 294 studies reached it within 52 months; a quarter within 28 and three quarters within 74.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2027 → Apr 2028 and completion May 2028 → Apr 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Drug: Gemcitabine/nab-paclitaxel · Drug: Cetuximab · Drug: Pembrolizumab · Drug: mFOLFOX6 · Drug: FOLFIRI · Drug: Pemetrexed · Drug: Carboplatin
KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel · KST-6051 Dose Escalation Combination Therapy with Cetuximab · KST-6051 Dose Escalation Combination Therapy with Pembrolizumab · KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors · KST-6051 Dose Expansion Monotherapy in Later-line Settings · KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel · KST-6051 Dose Expansion Combination Therapy with Cetuximab · KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI · KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin
Drug: Gemcitabine/nab-paclitaxel · Drug: Cetuximab · Drug: Pembrolizumab · Drug: mFOLFOX6 · Drug: FOLFIRI · Drug: Pemetrexed · Drug: Carboplatin
KST-6051 Dose Escalation Combination Therapy with Gemcitabine/Nab-paclitaxel · KST-6051 Dose Escalation Combination Therapy with Cetuximab · KST-6051 Dose Escalation Combination Therapy with Pembrolizumab · KST-6051 Dose Expansion Monotherapy in PDAC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in mCRC After 1 or 2 prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in NSCLC After 1 or 2 Prior Lines of Therapy · KST-6051 Dose Expansion Monotherapy in Prior RAS/KRAS Inhibitor-treated Solid Tumors · KST-6051 Dose Expansion Monotherapy in Later-line Settings · KST-6051 Dose Expansion Combination Therapy with Gemcitabine/nab-paclitaxel · KST-6051 Dose Expansion Combination Therapy with Cetuximab · KST-6051 Dose Expansion Combination Therapy with Cetuximab and mFOLFOX6 or FOLFIRI · KST-6051 Dose Expansion Combination Therapy with Pembrolizumab and Pemetrexed/carboplatin
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.